2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
8
Phase 2
5
Phase 1
5
Phase 3
3
Phase 4
2
Phase 1/2
2
Phase 2/3
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
1
CNS
1
Conditions
Neurofibromatosis 1
1
Lymphoma
1
Interventions
pembrolizumab
410
Cyclophosphamide
394
Carboplatin
306
Gemcitabine
286
Nivolumab
276
Paclitaxel
274
Cisplatin
252
Radiotherapy
225
Dexamethasone
210
Bevacizumab
209
fludarabine
192
Docetaxel
187
Rituximab
183
Capecitabine
171
Oxaliplatin
158
Lenalidomide
157
Fluorouracil
152
Temozolomide
138
Cytarabine
135
Etoposide
128
Irinotecan
124
Cetuximab
123
fludarabine phosphate
120
Injections
118
venetoclax
116
Ipilimumab
115
Doxorubicin
114
Azacitidine
108
130-nm albumin-bound paclitaxel
108
Pemetrexed
107
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Dosage Forms
×
Clear all
NCT05309668
2025-12-18
SPRINKLE
AstraZeneca
Phase 1/2
Active not recruiting
36 enrolled
37 charts
NCT03593187
2025-11-20
GENHIV
Assistance Publique - Hôpitaux de Paris
Phase 1/2
Completed
2 enrolled